Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: Post hoc time-course analysis of an all-case pms in Japan

Modern Rheumatology

Volumn 25, Issue 4, 2015, Pages 495-502

  Yamanaka, Hisashi ^a   Harigai, Masayoshi ^b   Ishiguro, Naoki ^c   Inokuma, Shigeko ^d   Takei, Syuji ^e   Takeuchi, Tsutomu ^f   Tanaka, Yoshiya ^g   Suzuki, Haruko ^h   Shinmura, Yasuhiko ^h   Koike, Takao ⁱ  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^h ABBVIE INC   (United States)

ⁱ NTT CORPORATION   (Japan)

Author keywords

Adalimumab; Efectiveness; Post marketing surveillance; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DAS28; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL PATIENT; HUMAN; INFECTION; INJECTION SITE REACTION; JAPAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INCIDENCE; PROCEDURES; TREATMENT OUTCOME;

ADALIMUMAB; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; JAPAN; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME;

EID: 84935032789     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.994263     Document Type: Article

References (20)

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 Suppl 1):1–12.
2. Shiokawa Y. Rheumatic diseases at the dawn of the millennium. J Rheumatol. 2003;30(Suppl 67):1–2.
3. Mugitani M. Japan: strategy for rheumatic disease control. J Rheumatol. 2003;30(Suppl 67):47.
4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid ar t hr itis. Lancet. 2007; 370: 1861–74.
5. Smolen JS, Aletaha D, Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nature Rev Rheumatol. 2012;8:235–43.
6. Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17(4):283–9.
7. Yamanaka H, Seto Y, Tanaka E, Furuya T, Nakajima A, Ikari K, et al. Management of rheumatoid arthritis: the 2012 perspective. Mod Rheumatol. 2013;23(1):1–7.
8. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and eff ectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the fi rst 3,000 patients. Mod Rheumatol. 2012;22(4):498–508.
9. Miyasaka N, CHANGE Study Investigators. Clinical investigation in highly disease-aff ected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18(3):252–62.
10. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profi le of infl iximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–94.
11. HUMIRA (adalimumab) prescribing information (in Japanese) [online]. Available from the Japanese pharmaceuticals and medical devices agency web site URL: http://www.info.pmda.go.jp/downfi les/ph/PDF/112130_3999426G1024_2_01.pdf. Accessed 23 May 2013.
12. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infl iximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17(6):451–8.
13. Hyrich KL, Watson KD, Lunt M, Symmons DP; British Society for Rheumatology Biologics Register (BSRBR). Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumor necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology. 2011;50(1):117–23.
14. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and eff ectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the 7740 patients. Mod Rheumatol. Published online 31 October 2013.
15. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and eff ectiveness of etanercept in Japan. J Rheumatol. 2009;36(5):898–906.
16. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and eff ectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21(4):343–51.
17. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19(4):351–7.
18. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Safety and eff ectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis. Rheumatol Int. 2012;32(6):1511–9.
19. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54(4):1063–74
20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classifi cation criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.